A document has been shared with you via Bill.com.
Confirm your email address to gain access.
During the fourth quarter of fiscal year 2025, the organisation delivered record revenue of $63.9 million, representing a 21.4% year-over-year increase driven by accelerating enterprise adoption, expanded product capability, and disciplined cost management across all operating segments. EBITDA margins improved to 31.2%, up from 26.8% in Q4 FY2024, reflecting operating leverage and strategic headcount optimisation initiated in Q2.
Full-year revenue reached $222.3 million against a budget of $214.0 million, a $8.3 million outperformance. Cash and short-term equivalents stand at $47.6 million, providing sufficient runway for the planned infrastructure investments outlined in the FY2026 strategic plan. The Board is advised to review the forward guidance assumptions detailed in Section 4 prior to the February earnings call.
| Line Item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | FY2025 |
|---|---|---|---|---|---|
| Product Revenue | $34.1 | $38.4 | $41.2 | $44.7 | $158.4 |
| Services Revenue | $13.1 | $14.4 | $17.2 | $19.2 | $63.9 |
| Total Revenue | $47.2 | $52.8 | $58.4 | $63.9 | $222.3 |
| COGS | $14.2 | $15.8 | $17.1 | $18.2 | $65.3 |
| Gross Profit | $33.0 | $37.0 | $41.3 | $45.7 | $157.0 |
| Operating Expenses | $20.4 | $22.1 | $23.6 | $25.8 | $91.9 |
| EBITDA | $12.6 | $14.9 | $17.7 | $19.9 | $65.1 |
| Net Income | $9.1 | $11.2 | $13.8 | $15.6 | $49.7 |
| EPS (Diluted) | $0.34 | $0.41 | $0.51 | $0.58 | $1.84 |
* All figures unaudited. Subject to revision pending external audit completion (expected March 14, 2026).
Management is guiding for full-year FY2026 revenue in the range of $265–$278 million (19–25% growth), contingent on successful completion of the planned Series D financing and the pending acquisition referenced in Board Resolution 2025-11. EBITDA margin expansion of 200–350 basis points is expected as the organisation achieves greater operating leverage on its fixed cost base.
The Board should note that the [REDACTED — Section 4.2] transaction described in the executive session materials remains subject to regulatory review and is classified as board-level confidential until further notice. Distribution of this document outside the approved recipient list constitutes a breach of the confidentiality agreement dated January 6, 2026.